CompletedNCT00237913
Aripiprazole or usual care for schizophrenia
About this title
Read the official source — NCT00237913Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Vienna and 32 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 700
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Austria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00237913
- Official title
Show the full official title
A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna, Austria · Přerov, Czechia · Copenhagen, Denmark
31 more locations
- Hørsholm, Denmark
- Helsinki, Finland
- Brumath, France
- Dole, France
- Hénin-Beaumont, France
- Jonzac, France
- Nantes Orvault, France
- Paris, France
- Reims, France
- Rennes, France
- Toulouse, France
- Uzès, France
- Duisburg, Germany
- Hattingen, Germany
- München, Germany
- Nuremberg, Germany
- Oldenburg, Germany
- Murcia, Spain
- Bromma, Sweden
- Gothenburgh, Sweden
- Halmstad, Sweden
- Malmö, Sweden
- Säter, Sweden
- Belfast, United Kingdom
- London, United Kingdom
- Royal Tunbridge Wells, United Kingdom
- Glasgow, United Kingdom
- Davyhulme, United Kingdom
- South Wales, United Kingdom
- Birmingham, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Olanzapine or Quetiapine or Risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
